Trials / Completed
CompletedNCT02182024
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To assess the effect of different degrees of renal impairment on the pharmacokinetics and pharmacodynamics of dabigatran etexilate administered orally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran etexilate high dose | |
| DRUG | Dabigatran etexilate low dose |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-03-01
- First posted
- 2014-07-08
- Last updated
- 2014-07-18
Source: ClinicalTrials.gov record NCT02182024. Inclusion in this directory is not an endorsement.